Fireside Chat Replay: Latest Developments in Oncology Supportive Care

On-demand webinar

Published on:
May 19, 2022

This discussion centers primarily around an area which is critical to physicians and patients, but often not the focus of the big research dollars being invested in the development of novel therapeutics: Oncology Supportive Care. Oncology Supportive Care focuses on all side effects or toxicities of treatments for cancer and is vital for ensuring that the adverse effects of cancer treatments are appropriately addressed, which has a direct impact on patients’ lives.  

In this fireside chat, we sat down with two medical experts in oncology and discuss some of the fascinating developments that are happening in the oncology supportive care field. We also spoke about how to balance commercial and patient-centric approaches when developing oncology supportive products, including the importance of health economic data and appropriately assessing the quality of life outcomes.  

During this fireside chat you will learn: 

  • What are the biggest patient concerns when it comes to current treatments for the side effects of cancer therapy
  • What has changed in oncology supportive care in the last 5 years, from both a patient and physician perspective
  • What are the health care economic factors that should be considered when developing a new oncology supportive care therapeutic

Meet the speakers

Harry Barnett – Executive Vice President, Clinical, Alira Health

Harry’s life science career includes co-founding and executive-level management of three pharma/biotech startup companies and two CROs. With a 20-year career in biotech, Harry has successfully sold or licensed over 15 products with revenues exceeding $250 million. He is a regular speaker, moderator, and chairman at conferences worldwide, sought after for his expertise in technology commercialization and clinical trial management. 

Sanford Katz, MD, DABR, FACRO

Dr. Katz received his doctor of medicine at the University of Maryland School of Medicine and completed his training in Radiation Oncology in the Department of Radiation Medicine at Georgetown University Medical Center.  He is a Diplomate of the American Board of Radiology in the field of Radiation Oncology and is a Fellow of the American College of Radiation Oncology. 

Dr. Katz is in private practice at the Willis-Knighton Cancer and Proton Therapy Center in Shreveport, Louisiana, and maintains adjunct academic faculty positions at the Lousiana State University Health Sciences Center in the Departments of  Otolaryngology-Head and Neck Surgery, Radiology, and Oral and Maxillofacial Surgery, as well as in the Department of Radiation Oncology at Tulane University School of Medicine. 

Dr. Katz specializes in cancers of the head and neck with a special interest in the clinical development and application of pharmacologic and technological strategies designed to minimize cancer treatment-related toxicities.   

Rajesh V. Lalla, DDS, PhD 

Rajesh V. Lalla, DDS, PhD is a Professor and Associate Dean for Research at the UConn School of Dental Medicine. He is the immediate Past President of the Multinational Association of Supportive Care in Cancer (MASCC), an international multidisciplinary society of healthcare professionals dedicated to supportive care in cancer. Dr. Lalla has also served as Chair of the MASCC Guidelines Committee and Chair of the MASCC Mucositis Study Group.  

Dr. Lalla clinical and research interests are focused on oral side-effects of cancer therapy, including oral mucositis and other oral complications in oncology patients. He has published over 100 peer-reviewed articles and 12 book chapters/monographs, most of them dealing with oral complications of cancer therapy. He is a frequent speaker on this topic at national and international meetings. 

Related news

Publications September 16, 2022
Considerations for Analyzing and Interpreting Data from Biometric Monitoring Technologies in Clinical Trials
The rise of technology in clinical research allows us to capture meaningful aspects of health in clinical study participants.
Biometrics Clinical eCOA
Publications September 7, 2022
The Promise and Reality of Decentralized and Hybrid Clinical Trials in Europe Today
To understand the challenges related to hybrid and decentralized trials and ways to overcome them, we spoke with Dr. Hervé Solatges, Product Management, Evidence, and Innovation (DCT(...)
Clinical Decentralized Clinical Trials Hybrid Clinical Trials
Publications September 5, 2022
Taking In-Licensed Biologics to Market: Challenges, Complexities, and Ways to Overcome Them
Taking a biologic through drug development to market is highly complex and filled with challenges. To understand these challenges, their implications and how to overcome them, we spoke(...)
Biologics Clinical Drug Development
Events August 10, 2022
We are pleased to announce that we will be sponsoring and attending DPHARM, a unique event focused on the latest innovations that modernize clinical trials.
Clinical Decentralized Clinical Trials DPHARM Patient Centric
Publications August 2, 2022
GMP Manufacturing and IND-Enabling Studies of a Recombinant Hyperimmune Globulin Targeting SARS-CoV-2
The last two years have brought forward tremendous advances in the development of prophylactic and therapeutic approaches for the treatment of SARS-CoV-2 infections.
Clinical CMC Vaccines
Multimedia May 19, 2022
Fireside Chat Replay: Latest Developments in Oncology Supportive Care
In this fireside chat, we sit down with two medical experts in oncology and discuss some of the fascinating developments that are happening in the oncology supportive care field.
Events May 19, 2022
DIA 2022 Global Annual Meeting
We are pleased to announce that we will be joining DIA 2022 Global Annual Meeting as exhibitors and delegates.
Biometrics Clinical Life Sciences Regulatory
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.